MétaCan
Menu
Back to cohort

Safety of Intravascular Administration of Umbilical-cord Derived Mesenchymal Stromal Cells: An Updated Systematic Review and Meta-analysis

2025· article· en· W4410271931 on OpenAlexaff
Jessica Poliwoda, Christine Hum, Manoj M. Lalu, Douglas A. Stewart, S.H.-J. Mei, Dean Fergusson, Lauralyn McIntyre

Bibliographic record

VenueAmerican Journal of Respiratory and Critical Care Medicine · 2025
Typearticle
Languageen
FieldMedicine
TopicMesenchymal stem cell research
Canadian institutionsOttawa HospitalUniversity of Ottawa
Fundersnot available
KeywordsMedicineUmbilical cordMesenchymal stem cellMeta-analysisPathologyImmunology

Abstract

fetched live from OpenAlex

Abstract Rationale: Mesenchymal stem cells (MSCs), in particular umbilical cord-derived MSCs (UC-MSCs), have the capacity to self-renew and exert immunomodulatory and paracrine effects. Our previously published safety systematic review of 55 randomized controlled trials (RCTs), which included 16 trials with UC MSCs, found that MSCs demonstrated a favourable safety profile, with the exception of fever that was more frequent for the MSC as compared to the control group. Our team is conducting a Phase II RCT of UC-MSC therapy in septic shock. Hence, we sought to evaluate and update the safety profile of UC-MSC therapy specifically as several more UC-MSC RCTs have been published since our previous review in 2019. Methods: We conducted a systematic search on Embase, Ovid MEDLINE, and Cochrane Central Register of Controlled Trials up to April 15, 2024. RCTs that compared intravascular delivery of UC-MSCs (intravenously or intra-arterially) in adult populations compared to a control group that did not receive UC-MSCs were identified. The primary outcome was categorized based on the following pre-specified adverse events: (1) fever within 24 h of drug administration, (2) non-fever acute infusional toxicity within 24 h of drug administration, (3) infection, (4) death, (5) malignancy/ectopic tissue formation, (6) thrombo-embolic events, and (7) mycotic aneurysms. Pre-specified adverse events were pooled and meta-analyzed by fitting inverse-variance binary random effects models where appropriate. Results: A total of 8094 studies were screened and 37 studies met eligibility criteria (n=1980 patients). The studies included a diverse patient population with a wide range of conditions, including cardiovascular (n=3), neurological (n=1), oncological/hematological (n=3), endocrine diseases (n=4), renal (n=1), hepatic (n=3), respiratory (n=16), and immune-deficient or inflammatory disorders (n=6). No significant safety signals were found for UC-MSCs as compared to controls for any prespecified adverse events (fever (relative risk (RR)= 1.60, 95% Confidence Interval (CI)= 0.90-2.86), non-fever acute infusional toxicity (RR= 1.04, 95% CI = 0.71-1.52), infection (RR= 0.78, 95% CI= 0.43-1.40), death (RR= 0.88, 95% CI= 0.72-1.08), thrombo-embolic event (RR= 0.80, 95% CI= 0.47-1.36), aneurysms (RR= 0.94, CI= 0.72-1.22) or malignancy (RR= 0.79, 95% CI= 0.64-0.98)). No included trials ended early due to safety concerns. Conclusion: UC-MSC therapy continues to appear safe for study in heterogeneous patient populations.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.011
metaresearch head score (Gemma)0.036
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (broad)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.985
Threshold uncertainty score0.060

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0110.036
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0150.021
Bibliometrics0.0080.008
Science and technology studies0.0000.001
Scholarly communication0.0030.002
Open science0.0020.001
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.042
GPT teacher head0.380
Teacher spread0.338 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAmerican Journal of Respiratory and Critical Care MedicineSame topicMesenchymal stem cell researchFrench-language works237,207